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Abstract The strategy to reprogram somatic stem cells to
pluripotency status has provided an alternative source of
surrogate ES cells (ESC). We report efficient reprogram-
ming of multipotent bone marrow (BM) mesenchymal stem
cells (MSC) to pluripotent status and the resultant MSC
derived iPS cells (MiPS) and their derived progenitors
effectively repaired the infarcted heart. MSC from young,
male, Oct4-GFP transgenic mice were reprogrammed by
retroviral transduction with Oct4, Sox2, Klf4, and c-Myc
stemness factors. MiPS thus generated displayed character-
istics of mouse ESC including morphology, surface antigens,
gene and miR expression profiles. MiPS also formed spon-
taneously beating cardiac progenitors which expressed car-
diac specific transcription factors and protein markers
including Gata4, Mef2c, Nkx2.5, myosin heavy chain, tro-
ponin-I, and troponin-T, and showed ultra structural char-
acteristics typical of cardiomyocytes. Intramyocardial
delivery of MiPS (group-2) and their derivative cardiac-like
cells (MiPS-CP; group-3) in a mouse model of acute myo-
cardial infarction showed extensive survival and engraft-
ment at 4 weeks with resultant attenuation of infarct size
(p \ 0.001 vs. DMEM injected control; n = 4). Engraft-
ment of MiPS-CP was without cardiac tumorigenesis as
compared to 21 % in MiPS transplanted animals. Further-
more, angiogenesis was improved in groups-2 and 3
(p \ 0.001 vs. control). Transthoracic echocardiography
revealed significantly preserved indices of cardiac contrac-
tility (ejection fraction p \ 0.001 and fractional shortening
p \ 0.001 vs. control; n = 7). MSC were successfully
reprogrammed into MiPS that displayed ESC-like charac-
teristics and differentiated into spontaneously beating
cardiomyocytes. Cardiac progenitors derived from MiPS
repopulated the infarcted heart without tumorigenesis and
improved global cardiac function.
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Introduction
The cytokine rich microenvironment of the infarcted
myocardium infiltrated by inflammatory cells and activa-
tion of various signaling pathways as part of the intrinsic
repair mechanism remains a major challenge in cardio-
vascular therapeutics [22, 27, 38]. In this regard, heart cell
therapy involving mobilization of stem cells from an
intrinsic pool in the body or by transplantation of stem cells
as an outside intervention has shown significant promise as
a therapeutic modality for ischemic heart disease [6, 7, 11,
15, 29, 30]. Given the multilineage differentiation capacity
and autologous availability, bone marrow (BM) derived
mesenchymal stem cells (MSC), with or without genetic
modification, have been extensively studied for myocardial
reparability [7, 26, 29]. Besides, paracrine release of bio-
active molecules by MSC contributes to improved heart
function via pro-survival effects on the host cardiomyo-
cytes and initiation of angiogenic response in the infarcted
myocardium [36]. We hypothesized that reprogramming of
MSC would improve their cardiomyogenic capabilities and
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proposed that induced pluripotent stem cells (iPSC)
derived from MSC (MiPS) would be more amenable to
differentiation into cardiac progenitors (CP). Furthermore,
MiPS would be superior to fibroblast-derived iPSC (FiPS)
as they might carry forward the epigenetic memory of
myogenic and angiogenic traits.
We report successful reprogramming of MSC using the
classical four-factor cocktail into MiPS which were
identical to mouse ESC and displayed potential for car-
diac differentiation in vitro by forming spontaneously
beating clusters of cardiac progenitors. Similar to previous
reports, we observed that MiPS engrafted efficiently to
prevent left ventricular (LV) remodeling and preserved
global heart function [2, 20]. However, unlike Nelson
et al., we observed formation of teratomas in the heart
after undifferentiated MiPS transplantation in immuno-
competent mice. This is consistent with our previous
findings using skeletal myoblast derived iPSC [1].
Therefore, differentiation of MiPS into cardiac progenitors
(MiPS-CP) curtailed their tumorigenicity and significantly
enhanced their engraftment capacity which led to reduced
LV remodeling, attenuated infarct size and improved heart
function. Similar to native MSC, MiPS-CP also displayed
an improved angiogenic response in the infarcted heart.
We found no teratomas in MiPS-CP transplanted animal
hearts due to altered expression of cardiac differentiation-
related and tumor-suppressive genes and miRs, respec-
tively, thus demonstrating that differentiation of MiPS
into CP may be safer and more applicable for stem cell
therapy.
Materials and methods
The present study conformed to the guide for the care and
use of laboratory animals published by the US National
Institutes of Health (NIH Publication No. 85–23, revised-
1985) and protocol approved by the Institutional Animal
Care and Use Committee, University of Cincinnati.
Isolation and characterization of MSC
MSC were purified from young (4–6 weeks) male, Oct4-
GFP transgenic mice (Jackson Laboratories, USA) with
GFP tagged to endogenous Oct4 gene promoter as detailed
in Supplementary data. Briefly, bones were isolated and
flushed with high glucose Dulbecco’s modified Eagle’s
medium (DMEM; 10 % fetal bovine serum and 0.5 %
penicillin/streptomycin) [36]. The adherent MSC were
propagated and maintained in high glucose DMEM at
37 C, 5 %CO2 atmosphere. The cells were maintained and
expanded for no more than three passages before use in
subsequent experiments.
The adherent cells were harvested with 0.025 % trypsin
(Sigma Aldrich, MO, USA) and analyzed by flow cytom-
etry (BD FACSCanto, BD Biosciences, NJ, USA) for
surface marker expression as detailed in Supplementary
data.
Generation of iPSC
Retroviral vectors encoding for the Yamanaka stemness
factors Oct4, Sox2, Klf4 and C-Myc were purchased from
Addgene Inc., USA (plasmid #13367, #13366, #13370,
#17220 from Takahashi et al.) [34]. The viruses were used
for transduction of mouse embryo fibroblasts (MEF: Global
Stem, MD, USA) and MSC for generation of FiPS and
MiPS, respectively. Plasmids for each of the pluripotency
factors and the envelope protein VSV-G plasmid were
transduced into GP2-293 packaging cells using CalPhos
Mammalian Transfection Kit (Clontech, CA, USA). After
72 h, supernatant was collected from each of the four
vectors, mixed together and centrifuged at 1,200 rpm for
5 min. The combined viral supernatant was passed through
a 0.45 lm cellulose acetate filter and used for transduction
of MSC or MEF. Briefly, 24 h before retroviral infection,
low passage MSC or MEF (passage 2–3) were seeded in
6-well plates at a density of 2 9 105 cells/well. The cells
were incubated for 42 h in supernatants containing the
vectors encoding for the stemness factors followed by
culture for 48 h in fresh complete growth medium. The
cells were re-plated in a 10 cm culture dish with irradiated
MEF on 0.1 % gelatin using mouse ESC medium. Mouse
ESC medium was replenished every other day as cells were
observed for growth of iPSC clones [2]. After 18–21 days,
iPSC clones displaying ESC-like morphology were
mechanically isolated and cultured on irradiated MEF. The
iPSC clones were propagated individually in ESC culture
medium.
Clones of iPSC were cultured on irradiated MEF
(5 9 104 cells/cm2) in ESC culture medium that consisted
of KnockoutTM DMEM supplemented with 15 % Knock-
outTM serum replacement, 0.5 % penicillin/streptomycin,
0.1 mmol/L non-essential amino acids, 0.2 mmol/L L-glu-
tamine, 0.1 mmol/L mercaptoethanol (Invitrogen, CA,
USA), and 103 U ml-1 leukemia inhibitory factor (LIF;
Millipore, CA, USA). The iPSC were characterized by
alkaline phosphatase staining, immunocytochemistry [1],
DNA methyltransferase activity assay, teratoma formation
and karyotyping as described in Supplementary data.
In vitro cardiac differentiation of MiPS
MiPS (2 9 106 cells/10 ml medium) were grown in sus-
pension for 3 days in high glucose DMEM containing
10 % FBS, 0.5 % penicillin/streptomycin, 0.1 mmol/L
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non-essential amino acids, and 0.1 mmol/L mercap-
toethanol) [2]. After 3 days in suspension, embryoid bodies
(EBs) were plated on 0.1 % gelatin-coated tissue culture
dishes (500–1,000 EBs/10 cm dish) and cultured for
another 7–10 days. Spontaneously contracting regions
were mechanically isolated and dissociated for cardiac
specific markers, ultra-structure studies and miR expres-
sion profiling as described in Supplementary data.
In vitro studies of anoxia-induced angiogenic factors
Native MSC, MiPS, MiPS-CP, FiPS or MEF were serum-
starved for overnight. Cells were treated with two 30 min
cycles of anoxia with one 10 min re-oxygenation in
between. Control cells for each group were maintained at
normal oxygen levels. The cells were immediately har-
vested and analyzed by RT-PCR for fibroblast growth
factor (FGF) and vascular endothelial growth factor
(VEGF) expression.
Experimental animal model of coronary artery ligation
and MiPS transplantation
An acute myocardial infarction model was developed in
8–12 week-old immunocompetent female C57BL/6 mice
[36]. Animals were anesthetized (Ketamine/Xylazine
0.05 ml intraperitoneally) and intubated. The heart was
exposed by minimal left sided thoracotomy and coronary
artery was permanently ligated. The animals were grouped
to receive intramyocardial injections of 20 ll basal DMEM
without cells (control), or 2 9 105 MSC (group-1), MiPS
(group-2), MiPS-CP (group-3), FiPS (group-4), or MEF
(group-5). The cells were labeled with red fluorescent
Q-tracker-625 (Invitrogen, CA, USA) to study the fate of
the cells post-transplantation in the infarcted heart. Heart
function was determined by transthoracic echocardiogra-
phy (Supplementary data). The animals were harvested for
histological studies at stipulated time-points.
Histological studies
Histological studies were performed as previously described
[2]. To measure infarction size, the hearts were arrested in
diastole by intravenously injecting them with cadmium
chloride followed by fixation in 10 % formalin. The hearts
were cut transversely and embedded in paraffin. Histological
sections were cut at 6 lm thickness and were stained with
Masson’s trichrome staining to visualize fibrosis. Cryosec-
tions were fixed with 4 % paraformaldehyde in PBS for
10 min and later incubated with CAS-BLOCK (Invitrogen,
CA, USA) for 1 h at room temperature. Slides were then
incubated with primary antibody overnight at 4 C (Sup-
plementary Table-II). Slides were then washed in PBS and
primary antigen–antibody reaction was detected using goat
anti-rabbit Alexa Fluor-488 conjugated secondary antibody
and goat anti-mouse Alexa Fluor-488 conjugated secondary
antibody (1:200, Invitrogen, CA, USA).
Statistical analysis
All data presented were described as mean ± SEM. One-
way analysis of variance with Holm-Sidak method was
used to determine significant differences between experi-




Native MSC were isolated from Oct4-GFP transgenic mice
and characterized by flow cytometry for MSC-specific
markers (Supplementary Figure-I). The cell population
used for reprogramming was 88.3 and 86.6 % pure for
CD44 and CD29, respectively whereas the cells were very
low in the expression for hematopoietic markers including
CD34 (1.1 %) and CD45 (1 %). Analysis for stemness
markers by RT-PCR showed that native MSC endoge-
nously expressed three of the four Yamanaka stemness
factors, including Sox2, Klf4, and c-Myc (Fig. 1a). MSC
were successfully reprogrammed into MiPS by simulta-
neous overexpression of stemness factors including Oct4,
Sox2, Klf4, and c-Myc. The efficiency of the reprogram-
ming was 0.01 %. Reprogrammed MSC were similar to
ESC in morphology and formed round, compact colonies
with tight margins and clearly defined edges as early as
18 days post-transduction (Fig. 1b panel a). Furthermore,
successful reprogramming of MSC was confirmed by the
newly formed MiPS colonies expressing GFP (green fluo-
rescence) as the cells were expressing endogenous Oct4-
GFP (Fig. 1b panel b). Similar to fibroblast-derived iPSC
(FiPS), endogenous levels of the stemness factors Oct4,
Sox2, Klf4, and c-Myc were increased in MiPS besides
expression of other pluripotency gene markers such as
Nanog, ESC-specific gene 1 (Esg1), fibroblast growth
factor 4 (Fgf4), growth and differentiation factor 3 (Gdf3),
and telomerase reverse transcriptase (TERT) (Fig. 1c). On
the other hand, exogenous transgene expression of the four
stemness factors was diminished in MiPS thus suggesting
their fully reprogrammed state (Supplementary Figure-
IIA). Percent methylation of Oct4 and Nanog promoters
was significantly reduced in MiPS (4.1 ± 0.4 %; 10.5 ±
2.7 %) and FiPS (5.0 ± 0.9 %; 6.9 ± 0.8 %) vs. native
MSC (63.9 ± 9.1 %; 43.9 ± 15.9 %) and MEF (58.6 ±
6.3 %; 53.2 ± 11.0 %), which confirmed the successful
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Fig. 1 Overexpression of the four stemness factors led to repro-
gramming of MSC. A RT-PCR for endogenous expression of
stemness factors in native MSC (lane-1 MSC, lane-2 MiPS clone,
lane-3 mouse ESC, lane-4 negative control, lane-5 MEF, lane-6
FiPS). B 18–21 days after four-factor transduction, a typical ESC-like
morphology was observed in MiPS clones; a phase-contrast and
b fluorescent images of Oct4/GFP ? MiPS colonies. c Fluorescence
immunostaining of MiPS for SSEA-1 (red). Nuclei were visualized by
DAPI staining (blue). d MiPS stained positive for alkaline phospha-
tase (dark red). C RT-PCR for ESC-specific gene expression in MiPS
(lane-1 MSC, lane-2 MiPS clone, lane-3 mouse ESC, lane-4 negative
control, lane-5 MEF, lane-6 FiPS). GAPDH was used as a loading
control. D Relative miR expression for pluripotency and differenti-
ation-related miRs, respectively during reprogramming of MSC.
(Original magnifications: a and b 920, c 20 9 1.6, d 910)
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reprogramming of the respective somatic cell type to plu-
ripotent status (Supplementary Figure-IIB). Using Oct4
and Nanog promoter methylation status in various cell
types as a positive control, although the change was
insignificant, we observed a decrease in percent methyla-
tion of Flk1 in MiPS (1.9 ± 0.6 %) and FiPS
(2.2 ± 0.6 %) as compared to MSC (5.8 ± 1.0 %) and
MEF (3.9 ± 0.6 %), respectively (Supplementary Figure-
IIB). A comparison of MSC and MiPS were positive for
ESC-specific markers SSEA-1, Oct4, and Sox2 (Fig. 1b
panel c and Supplementary Figure-IIC). MiPS also dis-
played a high level of alkaline phosphatase activity similar
to ESC (Fig. 1b panel d). During induction of MSC to a
pluripotent state, MiPS miR profile was altered resembling
more of a ESC-specific miR expression pattern. Specifi-
cally, during the transition of MSC to a pluripotent status,
the ESC-specific miR-290-295 cluster was upregulated in
MiPS (Fig. 1d) and unlike native MSC, the differentiation-
related let-7 family was almost abrogated in MiPS
comparable to let-7 expression levels in ESC (Fig. 1d).
Furthermore, DNA methyltransferase activity in MiPS
was insignificantly different from ESC (Supplementary
Figure-IIIA). Karyotyping showed that more than 70 % of
MiPS clones were euploid (Supplementary Figure-IIIB).
Pluripotency of MiPS was confirmed by teratogenic-
ity subsequent to subcutaneous injection of the cells
into immunodeficient nude mice (n = 3; Supplementary
Figure-IV).
In vitro cardiogenic differentiation of MiPS
Using the standard EB differentiation protocol, MiPS were
successfully differentiated into cardiomyocyte-like cells.
MiPS were allowed to form aggregates in suspension cul-
ture and after 3 days in differentiation culture medium,
EBs were transferred to adherent culture dishes. After
culture for another 5–7 days, spontaneously beating
regions of cells were observed (Supplementary Video-1).
The beating CP derived from MiPS (MiPS-CP) were
positive for cardiac-specific transcription factors and
myogenic markers including GATA4, myocyte enhancer
factor-2c (MEF2c), Nkx2.5, myosin heavy chain (aMHC
and bMHC) and cardiac troponin-T (Fig. 2a). Mouse heart
tissue was used as a positive control. Furthermore, gene
expression of pluripotency markers Oct4, Sox2, Nanog,
Klf4, and c-Myc was downregulated during MiPS differ-
entiation into MiPS-CP (Fig. 2b). Fluorescence immuno-
staining confirmed that MiPS-CP expressed cardiac
markers including cardiac troponin-I, Nkx2.5, and gap
junction proteins connexin-43 and N-cadherin (Fig. 2c).
Analysis of undifferentiated MiPS by transmission electron
microscopy revealed a high nucleus to cytoplasm ratio
(Fig. 2d). On the other hand, cells isolated from the
spontaneously beating EBs contained highly organized
striated fibers indicative of their spontaneous differentia-
tion into beating cardiomyocytes (Fig. 2e).
miR expression profiling of MiPS and MiPS-CP
miR expression profiles revealed changes in miR expres-
sion during cardiac differentiation of MiPS (Fig. 3a).
During MiPS differentiation into MiPS-CP, the embryonic-
associated miR-290–295 cluster was significantly down-
regulated (Fig. 3b). Conversely, there was a significant
increase in expression of differentiation-related miRs,
including the let-7 family as well as miRs that were
expressed in cardiac progenitors and regulated muscle
differentiation (Fig. 3c). Differentiation of MiPS into car-
diac progenitors also resulted in upregulation of tumor
suppressor miRs including miR-125b, miR-145, miR-16,
miR-199a, miR-21, miR-22, and miR-23a-24-27a cluster
(Fig. 3d). We also observed changes in miRs that regulated
angiogenic growth factors such as VEGF. MiPS subjected
to anoxia showed downregulation of miR-20a and miR-
20b, miRs which suppress VEGF expression (Fig. 3e).
MiPS and derivatives attenuated infarction size
expansion
To determine cardiac reparability of MiPS and MiPS-CP,
the cells were transplanted into the heart in an immuno-
competent mouse model of myocardial infarction. After
4 weeks of respective treatments, histological studies
(n = 4/group), showed the damaged area of the LV wall
which was evident from formation of scar tissue (Fig. 4a).
However, the cell transplanted groups including MSC
(26.6 ± 1.6 %), MiPS (21.9 ± 1.7 %), MiPS-CP (24.6 ±
2.7 %), and FiPS (27.3 ± 1.9 %) treatment groups had
attenuated infarction size and reduced LV wall thinning
(41.3 ± 3.8 %; p \ 0.001 vs. DMEM group; Fig. 4b).
Moreover, MSC, MiPS, and MiPS-CP had significantly
reduced infarction size compared to MEF group (38.0 ±
0.8 %; p \ 0.01).
Consistent with our previous report that transplantation
of undifferentiated iPSC formed cardiac tumors in immu-
nocompetent hosts [1], we observed cardiac tumors in
21 % of undifferentiated MiPS transplanted animals
(Fig. 4c). Immunohistological studies confirmed that the
cardiac tumors stained positive for cell surface markers
specific for all the three germ layers including endoderm
(a-fetoprotein), mesoderm (desmin), and ectoderm (b-tubulin)
(Fig. 4c and Supplementary Figure-V). No teratomas were
observed in native MSC and MiPS-CP transplanted animal
hearts.
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Fig. 2 Spontaneous cardiac differentiation of MiPS into beating cardio-
myocyte-like cells (MiPS-CP). a RT-PCR for cardiomyocyte-specific
genes in MiPS-CP on day ten after EB formation (lane-1 MiPS, lane-2
early non-beating day-6 EBs, lanes 3–4 MiPS-CP, lane-5 the heart, lane-
6 negative control). b Pluripotency specific gene expression was down-
regulated during spontaneous differentiation in vitro in parallel with
increased expression of cardiac specific genes (lane-1 MiPS, lane-2 early
non-beating day-6 EBs, lanes 3–4 MiPS-CP, lane-5 the heart, lane-6
negative control). c Fluorescence immunostaining of MiPS-CP for
cardiac-specific markers including cardiac troponin-I (red), Nkx2.5
(red), and gap-junction proteins connexin-43 (red) and N-cadherin (red).
Nuclei were stained with DAPI (blue) for visualization (original
magnifications: Tn-I = 9100; Nkx2.5, Cx-43, N-cad = 60 9 1.6). d,
e Transmission electron micrograph showing ultra-structure of d MiPS
with high nucleus to cytoplasmic ratio and e beating regions of the cells
generated by spontaneous differentiation displayed striated structure
resembling developing cardiomyocytes with z-lines and sarcomeric
organization (original magnifications: D = 910,000; E = 920,000)
Page 6 of 14 Basic Res Cardiol (2012) 107:301
123
Pro-angiogenic effects of MiPS and MiPS-CP
in the infarcted heart
We observed that native MSC expressed VEGF and FGF
under normal conditions which increased under anoxic
culture conditions (Fig. 5). Similar to native MSC, both
MiPS and MiPS-CP, as well as FiPS, expressed basal levels
of VEGF and FGF that were increased after anoxia. We
observed only low levels of VEGF and FGF expression in
anoxia treated MEF (Fig. 5) Consistent with these data,
significantly increased blood vessel density was observed
in the animal hearts 4 weeks after transplantation of native
MSC (8.8 ± 0.5; 11.5 ± 0.6), MiPS (9.1 ± 0.6; 12.8 ±
0.7), and MiPS-CP (9.1 ± 0.4; 12.9 ± 0.5) in the infarct
Fig. 3 miR profiling of MiPS during differentiation into cardiac
progenitors. a Heat map of miR expression profile in MSC, MiPS,
MiPS-anoxia treated cells, and MiPS-CP. Red and blue colors denote
miRs with upregulated and downregulated expression respectively.
b, c Fold change in the embryonic stem cell specific miR-290 cluster
and differentiation associated miRs including the let-7 family during
cardiac differentiation of MiPS. d Expression profile of tumor
suppressor miRs in MiPS-CP. e Fold changes in angiogenesis
regulating miRs showed a similar trend in MiPS-CP as in anoxia-
treated MiPS (MiPS-anoxia)
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and peri-infarct regions, respectively compared to control
animals (4.8 ± 0.5; 7.4 ± 0.4; p \ 0.001) (Fig. 6). Blood
vessel density was also improved in FiPS (5.9 ± 0.3;
10.2 ± 0.5) transplanted animals in the peri-infarct region
(p \ 0.01 vs. DMEM group). However, blood vessel
density was significantly higher in MSC, MiPS, and MiPS-
CP groups as compared to FiPS in the infarct region and in
MiPS and MiPS-CP as compared to FiPS in the peri-infarct
regions (p \ 0.01).
MiPS-CP differentiated into cardiomyocytes
in the infarcted heart
Extensive presence of Qdot (red fluorescence) labeled
MiPS-CP was observed at the site of the cell graft 4 weeks
after transplantation (Fig. 7a). Immunohistochemistry
revealed co-localization of myogenic marker a-sarcomeric
actinin (green) with red fluorescence in the infarct (Fig. 7b)
and peri-infarct (Fig. 7c) areas of the MiPS-CP trans-
planted hearts. Similarly, MiPS-CPs were also co-localized
with the angiogenic marker von Willebrand factor-VIII
(green) thus suggesting that several of the transplanted
cells were also incorporated into blood vessels (Fig. 7d).
Heart function studies
Four weeks after permanent LAD artery ligation, indices of
LV contractile function including LV ejection fraction
(LVEF) and fractional shortening (LVFS) were significantly
deteriorated in all the treatment groups (n = 7) as compared
to baseline controls (n = 4; 79.4 ± 2.6 %; 41.3 ± 2.4 %
respectively, p \ 0.001 vs. all cell transplanted groups). On
the contrary, cell transplantation led to significant improve-
ment in global heart function (Fig. 8a). As compared to
DMEM group (25.9 ± 2.1 %; 9.6 ± 0.8 %), LVEF and
LVFS were significantly improved in native MSC (47.4 ±
5.5 %; 19.8 ± 2.8 %), MiPS (54.8 ± 2.2 %; 23.4 ± 1.2 %),
and MiPS-CP treated animal hearts (52.4 ± 3.4 %; 22.2 ±
1.8 %). Furthermore, LVEF and LVFS in FiPS treatment
group were significantly improved (47.9 ± 5.9 %; 20.0 ±
3.1 %, respectively) and remained insignificantly changed in
MEF (39.1 ± 2.2 %; 15.3 ± 1.0 %) as compared to DMEM
group. Cell transplantation also prevented pathological
remodeling of the LV (Fig. 8b). LV chamber dimensions
during systole (LVIDs) and diastole (LVIDd) were signifi-
cantly improved (p \ 0.01) in both MiPS (3.1 ± 0.3 mm;
4.0 ± 0.3 mm, respectively) and MiPS-CP (3.6 ± 0.3 mm;
4.6 ± 0.3 mm) treated groups compared to DMEM controls
(5.4 ± 0.3 mm; 6.0 ± 0.3 mm). However, no significant
difference was observed in LVIDs or LVIDd in FiPS
(4.0 ± 0.5 mm; 5.0 ± 0.5 mm) and MEF (4.5 ± 0.5 mm;
5.3 ± 0.5 mm) treated groups as compared to DMEM group.
Discussion
The breakthrough discovery of somatic cell reprogram-
ming is a promising approach for the generation of
Fig. 4 Transplantation of MiPS-CP reduced infarction size.
a, b Masson’s trichrome staining 4 weeks after permanent LAD
ligation showed attenuated infarction size in various treatment groups
of animals (n = 4/group). Infarct size was significantly attenuated in
cell transplanted animal groups (MSC treated group-1, MiPS and
MiPS-CP treated groups-2 and 3, and FiPS group-4 * p \ 0.001 vs.
control). MSC, MiPS, and MiPS-CP treatment groups also had a
significantly reduced infarction size compared to MEF group-5
(#p \ 0.01). All values were expressed as mean ± SEM. c Tumor
found in undifferentiated MiPS transplanted heart 4 weeks after
treatment. The tumor expressed three germ layer markers including
alpha-fetoprotein (red), desmin (green), and beta-tubulin (red).
Nuclei were stained with DAPI (original magnification = 940)
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autologous, pluripotent stem cells for use in regenerative
medicine. Nevertheless, a few studies have focused on
myocardial reparability of iPSC [2, 20]. Moreover, these
studies have published conflicting results in terms of the
teratogenicity of the transplanted cells. Therefore, both
safety and efficacy of iPSC warrant in-depth and system-
atic assessment in experimental animal models. We
reprogrammed MSC using Yamanaka’s conventional four-
factor protocol [34] and determined the safety and efficacy
of MiPS and their derived MiPS-CP for myocardial repair.
The important findings of our study included: (1) Suc-
cessful and efficient reprogramming of MSC with four
stemness factors in MSC. (2) MiPS resembled ESC in
pluripotency gene and miR expression profiles and showed
spontaneous cardiogenesis. (3) Transplantation of MiPS
led to teratoma formation in the infarcted hearts of
immunocompetent hosts. (4) Transplantation of MiPS-CP
was safe and preserved infarcted heart function via angi-
omyogenic differentiation.
MSC constitute a heterogeneous group of cells some of
which also express primitive surface markers. Our RT-PCR
results confirmed that the cells used for reprogramming
expressed Sox2, Klf4 and c-Myc besides showing low Oct4
expression. Irrespective of the strategy and type of the
somatic cell used for reprogramming, iPSC display ESC-
like traits albeit with varying degree of reprogramming
efficiency and epigenetic characteristics which are related
to the parent cell [9]. Keratinocytes, having higher
endogenous Klf4 and c-Myc expression than fibroblasts,
were reprogrammed after only 10 days of viral transgene
expression as compared to weeks for complete repro-
gramming of fibroblasts [16]. Embryonic tissues in this
regard, provide the most ideal parent cell population due to
ease of reprogramming albeit for availability and ethical
issues associated with their use [18]. It is now becoming
more evident that iPSC retain the epigenetic memory of
their parent cells due to incomplete DNA methylation
patterns [8, 13, 23]. During transcription factor-based
reprogramming strategy, DNA demethylation occurs at a
slow rate and therefore, residual methylation can contribute
to preservation of parent cell methylation signatures [8].
Epigenetic differences between ESC and iPSC contribute
to altered differentiation potential in iPSC. It is therefore
critical to consider the type of parent cell used based on
tissue type and differentiation status [12, 13]. Comparison
of cardiogenic differentiation potential of human iPSC
derived from BM cells, skin fibroblasts, and hair kerati-
nocytes demonstrated that there was no significant differ-
ence in functionality of the cardiomyocytes derived from
each of the iPSC lines; however, BM-derived iPSC dis-
played significantly higher cardiac differentiation effi-
ciency than fibroblast and keratinocyte-derived iPSC [33].
Fig. 5 Paracrine behavior of MiPS and MiPS-CP is similar to native
MSC. a RT-PCR for angiogenic growth factors in different cell
groups under normoxia (N) and anoxic conditions (A). Expression of
VEGF was less in MEFs and FiPS compared to the other groups and
although FiPS did express FGF, there was a decrease in expression
after anoxia treatment, whereas there was an observed increase in
FGF in MSCs, MiPS and MiPS-CP after anoxia. b Quantitative
densitometry for angiogenic gene expression with GAPDH used as
loading control (* p \ 0.05 MEF normoxia and anoxia vs. all other
groups; n = 3)
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Using Flk1 as a model, we did not detect significant dif-
ferences in percent methylation between native MSCs vs.
MEFs. We also observed that percent methylation was
similar in MiPS vs. FiPS. Furthermore, the change in
percent methylation of Flk1 was not significant after
reprogramming of MSC and MEF. Future in-depth and
expansive studies would be required for more conclusive
evidence to infer the role of parent cell epigenetics as a
determinant of iPSC characteristics.
Given the autologous availability, multipotentiality and
presence of subpopulations expressing stemness factors
including Oct4, Nanog, alkaline phosphatase and SSEA-4
[28], we hypothesized that MSC provided a near optimal
source of cells for reprogramming to pluripotency as com-
pared to the conventionally used fibroblasts. Moreover,
having epigenetic memory of MSC, MiPS would be more
suitable for cardiac repair than fibroblasts as they can
regenerate muscle fibers in addition to improving
angiogenesis in the ischemic heart. Although our results
demonstrated no statistical significance in the efficacy of
MSC in comparison to its derivative MiPS and MiPS-CP,
the latter two showed higher and better preserved LVEF and
LVFS as well as LV diastolic and systolic dimensions as
compared to MSC treated animal hearts. Similarly, both
MiPS and MiPS-CP were as good as MSC in their response
to anoxia to release angiogenic growth factors in vitro and
enhanced angiogenesis in the heart. Based on these data,
MiPS-CP has advantage of being committed to cardiogenic
differentiation and therefore would be a better choice for
transplantation. Similarly, differentiation into cardiac-like
cells ensures tumor-free integration into the host myocar-
dium. However, further in-depth experimentation in larger
animal group size would be required for comprehensive
comparison of MSC with its derivative reprogrammed cells.
The capacity of BM stem cells to cross lineage restric-
tion and adopt myogenic as well as vasculogenic
Fig. 6 MiPS and MiPS-CP improved angiogenesis in the ischemic
heart. a Immunofluorescence staining of mouse heart tissue sections
from different treatment groups for von Willebrand factor-VIII at
4 weeks after their respective treatment. b Quantitative analysis
confirmed that MSC, MiPS, and MiPS-CP transplanted groups-1, 2,
and 3 showed significantly higher blood vessel density than both
DMEM controls and FiPS group-4 in the infarct region (* p \ 0.001).
In peri-infarcted areas, MiPS and MiPS-CP showed significantly
improved density compared to DMEM control and FiPS groups
(#p \ 0.01) while both MSC and FiPS were better than DMEM group
(* p \ 0.01). All values were expressed as mean ± SEM
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phenotypes after transplantation has been reported [10, 25,
29, 32]. However, limited cardiogenesis with BM stem
cells has always been a concern [14, 19]. Alternatively,
secretion of bioactive proangiogenic molecules, i.e. VEGF
and FGF, integral to paracrine activity of stem cells has
been implicated in cardioprotection either by pro-survival
signal transduction or by creating a favorable concentration
gradient in the heart to engage resident stem/progenitor
cells for angiomyogenic repair. The present study, how-
ever, was more focused on myocardial reparability of MiPS
and MiPS-CP and hence did not investigate the role of
endogenous cardiac progenitors in myocardial repair pro-
cess. Moreover, the use of genetic markers would be a
more appropriate choice in order to determine the angi-
ogmyogenic fate of the transplanted cells.
Undifferentiated iPSC, irrespective of their origin and
method of reprogramming, are inherently teratogenic post-
transplantation similar to undifferentiated ESC [21]. We
have already shown that transplantation of skeletal myo-
blast derived iPSC formed tumors in the hearts of
immunocompetent hosts [1] unlike the published data [20].
During the present study, similar rate of teratogenicity was
observed in the undifferentiated MiPS transplanted animal
hearts. However, in agreement with our previous study, we
did not observe teratomas in the hearts transplanted with
differentiated MiPS-CP isolated from spontaneously dif-
ferentiated EBs [2]. These data suggested that undifferen-
tiated iPSC were similar to ESC in tumorigenic potential
and therefore should be used with caution. Various strate-
gies are being developed ranging from optimization of
iPSC generation protocols to post-reprogramming manip-
ulation of reprogrammed cells prior to transplantation in
order to curtail their tumorigenic potential. For example,
purification of cardiac progenitors based on surface mark-
ers and their differentiation to cardiac-like cells may
enhance their cardiogenic potential without tumorigenicity
[42]. More recently, flow cytometry assisted isolation
method based on DNA contents and mitochondrial pro-
pensity have been developed to separate non-tumorigenic
ESC sub-lineages [5]. In the same context, cardiac-like
Fig. 7 Transplanted MiPS-CP
adopted angiomyogenic fate
post-transplantation.
a Histological sections showing
extensive presence of
Qdot-labeled MiPS-CP in the
infarcted heart 4 weeks after
transplantation. b,
c Immunostaining of MiPS-CP
transplanted hearts after
4 weeks indicated co-
localization of transplanted
MiPS-CP (red) and the
myogenic marker cardiac
a-sarcomeric actinin (green).
The red box in C indicates the
area that was magnified (below)
to show the transplanted
MiPS-CP (red) overlapping
with a-sarcomeric actinin
(green) in the infarcted region
of the myocardium.




MiPS-CP (red) with vWF-VIII
(green). Nuclei were stained
with DAPI (original
magnifications: a, b = 920;
c = 940; d = 9100)
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cells have been isolated with Percoll density gradient tak-
ing advantage of the size difference between ESC and their
derived myocytes [39, 41]. Although differentiation of
MiPS to MiPS-CP reduced the incidence of teratoma for-
mation in the heart, mechanical dissection approach to
isolate beating cardiomyocyte-like cells from the culture
has its limitations and may not be an ideal strategy to
ensure tumor-free use of iPSC.
With emergence of miRs as regulators of stem cell
pluripotency and differentiation potential [24], we
observed altered miR expression during reprogramming
and differentiation to form MiPS and MiPS-CP respec-
tively. We observed significant changes in miR-290 and
let-7 families which were determinant of pluripotent and
differentiated status of the cells, respectively. The miR-290
family are known ESC-specific cell cycle-regulating miRs
that help to ensure ESC differentiation when required. With
repression of Oct4, Sox2 and Nanog during spontaneous
differentiation of MiPS, a significant abrogation of miR-
290-295 and five to ten-fold increase in let-7 cluster was
observed. On a similar note, miR-143 and miR-145 that
regulate smooth muscle differentiation [40] as well as the
muscle-specific miR-26a [37] were also increased. These
data suggested that MiPS-CP expressed miRs which were
directly involved in muscle and vascular cell differentia-
tion. A comparison of miR expression profile showed that
differentiation of MiPS prior to transplantation increased
tumor-suppressor miRs thus reducing the chances of
tumorigenicity. We observed upregulated expression of
cell growth specific miRs including miR-125b, miR-145,
miR-16 and miR-199a during differentiation of MiPS into
MiPS-CP [31, 35]. MiPS-CP also showed increased
expression of miR-21, miR-22, and miR-23a-24-27a clus-
ter that function to inhibit cell growth and proliferation
either through suppression of Oct4, Sox2, and Nanog or by
targeting c-Myc [4, 17]. Interestingly, we also observed
decreased levels of miR-20a-b, the members of miR-17
family expressed in many cancers and may contribute to
tumor growth [3]. Both miR-20a-b target VEGF and under
hypoxic conditions, they are significantly down-regulated
in response to stabilization of hypoxia inducible factor-1a
(HIF-1a) [3]. These findings suggested that differentiation
Fig. 8 Transplantation of MiPS and MiPS-CP preserved global heart
function. a Heart function was determined by echocardiography
4 weeks after myocardial infarction and after appropriate cell
treatments. Treatment with MEFs did not significantly change heart
function. LVEF and LVFS were significantly improved in all other
cell transplanted groups as compared to basal DMEM injected control
(* p \ 0.001). Although there was a significant improvement in
ejection fraction in MiPS and MiPS-CP treated groups-2 and 3, there
were no significant differences between the cell transplanted groups.
b The DMEM-injected control animals also showed worsened LV
chamber dimensions 4 weeks post-infarction, whereas we observed
significantly preserved LV chamber dimensions during diastole
(LVIDd: * p \ 0.01 vs. DMEM) and systole (LVIDs: * p \ 0.01
vs. DMEM) in both MiPS and MiPS-CP treated groups-2 and 3. All
values were expressed as mean ± SEM. (n = 7; MSC n = 6; FiPS
n = 5; MEF n = 3)
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of MiPS into cardiac progenitors not only upregulated
genes and miRs involved in cardiac differentiation, but also
helped to reduce tumorigenicity. In conclusion, differenti-
ation of MiPS prior to transplantation is a safer option to
achieve tumor-free use of MiPS. However, protocols need
to be developed and optimized to ensure the purity of
MiPS-CP and determination of the level of differentiation
of MiPS towards cardiac commitment would ensure better
prognosis.
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